

## Confirmed Speakers

### Confirmed Plenary Speakers (to Date)

#### Applying CRISPR/CAS9 For Cancer Target Identification, Validation and Novel Treatment Combinations



Dr Roderick BEIJERSBERGEN  
(NETHERLANDS CANCER INSTITUTE, Amsterdam, The Netherlands)

#### Use of Cyclic Dinucleotides (CDNs) to Induce Stimulator of Interferon Genes (STING)-Dependent Antitumor Immunity



Dr Cedric BOULARAN  
(INVIVOGEN, TOULOUSE, France)

#### Synthetic Genetics: Beyond DNA and RNA



Dr Philipp HOLLIGER  
(MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge, United Kingdom)

(EYEDPHARMA)

#### 2'-Spiro-substituted Nucleosides Active against the Hepatitis C-virus



Dr Tim JONCKERS  
(JANSSEN INFECTIOUS DISEASES-DIAGNOSTICS BVBA, Beerse, Belgium)

#### Discovery of Novel DOT1L Inhibitors by Fragment Growing, Defragmentation and Fragment Linking



Dr Henrik MOEBITZ  
(NOVARTIS, Basel, Switzerland)

#### Local Target Structure Influences the Efficacy of Oligonucleotide-based Drugs



Prof. Georg SCZAKIEL  
(UNIVERSITY OF LÜBECK, Lübeck, Germany)